Verona Pharma PLC VRNA
We take great care to ensure that the data presented and summarized in this overview for Verona Pharma plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VRNA
View all-
Perceptive Advisors LLC New York, NY6.56MShares$591 Million17.44% of portfolio
-
Janus Henderson Group PLC London, X05.52MShares$497 Million0.2% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y93.92MShares$353 Million17.31% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.46MShares$312 Million13.82% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.89MShares$261 Million3.9% of portfolio
-
Rtw Investments, LP New York, NY2.85MShares$257 Million2.96% of portfolio
-
Nea Management Company, LLC Timonium, MD2.69MShares$242 Million16.19% of portfolio
-
Abingworth LLP London, X02.46MShares$221 Million21.3% of portfolio
-
Summit Partners Public Asset Management, LLC Boston, MA2.32MShares$209 Million4.47% of portfolio
-
Wellington Management Group LLP Boston, MA2.13MShares$192 Million0.03% of portfolio
Latest Institutional Activity in VRNA
Top Purchases
Top Sells
About VRNA
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Insider Transactions at VRNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 08
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
90,320
-0.72%
|
$993,520
$11.44 P/Share
|
|
Jul 08
2025
|
David Zaccardelli President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
90,320
-0.67%
|
$993,520
$11.44 P/Share
|
|
Jul 08
2025
|
Andrew Fisher General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
39,464
-8.85%
|
$434,104
$11.44 P/Share
|
|
Jul 08
2025
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
37,616
-1.43%
|
$413,776
$11.44 P/Share
|
|
Jul 07
2025
|
Mark W Hahn Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
229,512
+1.8%
|
-
|
|
Jul 07
2025
|
David Zaccardelli President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
229,512
+1.68%
|
-
|
|
Jul 07
2025
|
Andrew Fisher General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
86,064
+16.17%
|
-
|
|
Jul 07
2025
|
Kathleen A. Rickard Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
86,064
+3.17%
|
-
|
|
Jun 16
2025
|
Andrew Fisher General Counsel |
SELL
Open market or private sale
|
Direct |
80,000
-18.18%
|
$880,000
$11.53 P/Share
|
|
Jun 16
2025
|
Andrew Fisher General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
80,000
+15.38%
|
$160,000
$2.01 P/Share
|
|
Jun 11
2025
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
400,000
-2.94%
|
$4,400,000
$11.4 P/Share
|
|
Jun 11
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
400,000
-3.15%
|
$4,400,000
$11.4 P/Share
|
|
May 29
2025
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
208,696
-1.51%
|
$1,878,264
$9.33 P/Share
|
|
May 29
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
204,864
-1.59%
|
$1,843,776
$9.33 P/Share
|
|
May 28
2025
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
157,704
-1.13%
|
$1,419,336
$9.3 P/Share
|
|
May 28
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
162,704
-1.25%
|
$1,464,336
$9.3 P/Share
|
|
May 27
2025
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
33,600
-0.24%
|
$302,400
$9.53 P/Share
|
|
May 27
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
32,432
-0.25%
|
$291,888
$9.53 P/Share
|
|
May 20
2025
|
Vikas Sinha Director |
SELL
Open market or private sale
|
Direct |
160,000
-68.25%
|
$1,440,000
$9.39 P/Share
|
|
May 20
2025
|
Vikas Sinha Director |
BUY
Exercise of conversion of derivative security
|
Direct |
160,000
+40.56%
|
$0
$0.5 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 2.69M shares |
|---|---|
| Open market or private purchase | 137K shares |
| Grant, award, or other acquisition | 4.9M shares |
| Bona fide gift | 1 shares |
| Open market or private sale | 9.48M shares |
|---|---|
| Payment of exercise price or tax liability | 2.18M shares |
| Bona fide gift | 64K shares |